Abstract
Background:To compare the efficacy and safety of preoperative intravitreal injections of ranibizumab and conber-cept in Chinese proliferative diabetic retinopathy(PDR)patients.Methods:This prospective randomized controlled trial enrolled 90 eyes of 80 patients with PDR.Forty-four eyes of 40 patients that received intravitreal ranibizumab(IVR)injections(0.5 mg/0.05 mL)before vitreous surgeries were assigned to the IVR group.Forty-six eyes of 40 patients that received intravitreal conbercept(IVC)injections(0.5 mg/0.05 mL)before vitreous surgeries were assigned to the IVC group.Intraoperative and postoperative indices were assessed for further comparison between the two groups.Results:There were no statistically significant differences in all surgery indices,including intraoperative indices(sur-gery time,P=0.225;intraoperative bleeding,P=0.808;endodiathermy use,P=0.693;incidence of iatrogenic retinal breaks,P=0.740;relaxing retinotomy,P=0.682;retinal reattachment,P=0.682 and silicone oil tamponade,P=0.814)and postoperative indices[postoperative vitreous hemorrhage(VH),P=0.808;neovascular glaucoma(NVG),P=0.964;recurrent retinal detachment,P=0.531;postoperative fibrovascular proliferation progression,P=0.682 and reoperation,P=0.955]between the two groups.There were no statistically significant differences in best-corrected visual acuity(BCVA)at each follow-up visit(P=0.939,0.669,0.741 and 0.717,respectively)or in central retinal thick-ness(CRT)(P=0.976,0.699,0.551 and 0.686,respectively).As for safety profile,both groups had no ocular or system adverse events during the observation period.Conclusions:IVR and IVC as a pretreatment of vitrectomy had similar efficacy and safety profile for Chinese PDR patients.
万方数据